Respond to at least two of your colleagues’ posts (on different days) using the Annoto feature to post at least 2 Annoto comments per colleague video explaining why you agree or disagree with at least two elements of their videos (other than the title slide and references slide(s)).
Note: Your responses to colleagues should be substantial (at least 50 words minimum per comment), supported with scholarly evidence from your research and/or the Learning Resources, and properly cited using APA style. Your responses should enrich the initial post by supporting and/or adding a fresh viewpoint and be constructive.
SOLUTION
Response to Colleague 1 – Annoto Comment 1
I agree with your point about the importance of distinguishing anemia of chronic disease from iron-deficiency anemia. You clearly explained the diagnostic role of ferritin, TIBC, and transferrin saturation. This aligns with KDIGO guidelines, which emphasize evaluating iron status before starting erythropoietin therapy (KDIGO, 2012). Your explanation makes the diagnostic process very clear and clinically practical.
Reference:
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2012). KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements, 2(4), 279–335. https://kdigo.org/guidelines/anemia-in-ckd/
Response to Colleague 1 – Annoto Comment 2
I appreciate your caution about the risks of blood transfusions in patients with CKD. I agree that transfusion should not be the first-line approach unless the hemoglobin level is severely low or the patient is symptomatic. Research supports avoiding unnecessary transfusions to reduce alloimmunization and cardiovascular risks (Locatelli et al., 2018). You presented this in a way that was both evidence-based and patient-centered.
Reference:
Locatelli, F., Bárány, P., Covic, A., De Francisco, A., Del Vecchio, L., Goldsmith, D., … Vanholder, R. (2018). Kidney Disease: Improving Global Outcomes guidelines on anemia management in chronic kidney disease: A European Renal Best Practice position statement. Nephrology Dialysis Transplantation, 28(6), 1346–1359. https://doi.org/10.1093/ndt/gfs375
Response to Colleague 2 – Annoto Comment 1
I agree with your emphasis on monitoring hemoglobin levels closely when using erythropoiesis-stimulating agents. You made a strong point about avoiding hemoglobin targets above 13 g/dL, which is consistent with evidence that higher levels increase the risk of cardiovascular complications (Palmer et al., 2010). Your explanation highlighted the importance of balancing benefits with safety, which is essential in clinical practice.
Reference:
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Tonelli, M., Garg, A. X., … Strippoli, G. F. M. (2010). Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Annals of Internal Medicine, 153(1), 23–33. https://doi.org/10.7326/0003-4819-153-1-201007060-00252
Response to Colleague 2 – Annoto Comment 2
I respectfully disagree with your suggestion that oral iron should always be the first choice for supplementation in CKD-related anemia. While oral iron is useful in some patients, many CKD patients—especially those with advanced disease—have poor absorption and may benefit more from IV iron therapy. KDIGO guidelines recommend IV iron for patients with low ferritin and transferrin saturation who are not responsive to oral therapy (KDIGO, 2012). I think this distinction is important to individualize treatment.
Reference:
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. (2012). KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney International Supplements, 2(4), 279–335. https://kdigo.org/guidelines/anemia-in-ckd/
The post Annatto video comments appeared first on Skilled Papers.